{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EBV+Specific+T-Lymphocytes",
    "query": {
      "intervention": "EBV Specific T-Lymphocytes"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 68,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EBV+Specific+T-Lymphocytes&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T23:44:00.508Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02973113",
      "title": "Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NonHodgkin Lymphoma",
        "Lymphoproliferative Disorders",
        "EBV Related Lymphoma",
        "EBV-Related PTLD",
        "Hodgkin Lymphoma",
        "EBV Related Non-Hodgkin's Lymphoma",
        "EBV Related Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "EBVST Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 8,
      "start_date": "2016-02-16",
      "completion_date": "2020-07-11",
      "has_results": false,
      "last_update_posted_date": "2021-07-21",
      "last_synced_at": "2026-09-04T23:44:00.508Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02973113"
    },
    {
      "nct_id": "NCT01070797",
      "title": "Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenovirus Infection",
        "Epstein-Barr Virus Infections",
        "Cytomegalovirus Infections",
        "Stem Cell Transplant"
      ],
      "interventions": [
        {
          "name": "Multi-virus Specific T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 10,
      "start_date": "2011-01",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-09-04",
      "last_synced_at": "2026-09-04T23:44:00.508Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01070797"
    },
    {
      "nct_id": "NCT00834093",
      "title": "A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nasopharyngeal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Epstein-Barr Virus Specific Immunotherapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2009-04",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-09-04T23:44:00.508Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00834093"
    },
    {
      "nct_id": "NCT00058604",
      "title": "Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epstein-Barr Virus Infections",
        "Lymphoproliferative Disorders"
      ],
      "interventions": [
        {
          "name": "Intravenous injection of EBV specific CTLs",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 12,
      "start_date": "2001-01",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-09-04T23:44:00.508Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00058604"
    },
    {
      "nct_id": "NCT00002663",
      "title": "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "EBV-induced Lymphomas",
        "EBV-associated Malignancies",
        "Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma"
      ],
      "interventions": [
        {
          "name": "Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Atara Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 58,
      "start_date": "1995-03",
      "completion_date": "2019-07",
      "has_results": true,
      "last_update_posted_date": "2023-02-13",
      "last_synced_at": "2026-09-04T23:44:00.508Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002663"
    },
    {
      "nct_id": "NCT00953420",
      "title": "Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nasopharyngeal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "EBV-specific cytotoxic T lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "G-CSF or Peg-GCSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2009-11",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2017-08-18",
      "last_synced_at": "2026-09-04T23:44:00.508Z",
      "location_count": 3,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00953420"
    },
    {
      "nct_id": "NCT06909110",
      "title": "Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adenovirus",
        "Cytomegalovirus Infections",
        "Epstein-Barr Virus Infections"
      ],
      "interventions": [
        {
          "name": "Adenovirus Specific T- Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cytomegalovirus Specific T-Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Epstein-Barr Virus Specific T-Lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jessie L. Alexander",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "1 Month to 65 Years"
      },
      "enrollment_count": 25,
      "start_date": "2025-04-30",
      "completion_date": "2032-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-09-04T23:44:00.508Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06909110"
    },
    {
      "nct_id": "NCT02231853",
      "title": "Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "CML (Chronic Myelogenous Leukemia)",
        "MDS (Myelodysplastic Syndrome)",
        "Acute Lymphoblastic Leukemia",
        "AML (Acute Myelogenous Leukemia)"
      ],
      "interventions": [
        {
          "name": "MVST",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVSTr",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-09-03",
      "completion_date": "2017-12-29",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-09-04T23:44:00.508Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02231853"
    },
    {
      "nct_id": "NCT00085930",
      "title": "Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "EBV specific CTLs",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 19,
      "start_date": "2003-04",
      "completion_date": "2025-08",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-09-04T23:44:00.508Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085930"
    },
    {
      "nct_id": "NCT04364178",
      "title": "Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adenovirus",
        "Cytomegalovirus Infections",
        "Epstein-Barr Virus"
      ],
      "interventions": [
        {
          "name": "Adenovirus Specific T- Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cytomegalovirus Specific T-Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EBV Specific T-Lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jessie L. Alexander, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "1 Month to 65 Years"
      },
      "enrollment_count": 8,
      "start_date": "2020-08-12",
      "completion_date": "2023-11-11",
      "has_results": true,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-09-04T23:44:00.508Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04364178"
    }
  ]
}